Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer

Resistance to docetaxel is a major clinical problem in advanced prostate cancer (PCa). Although glucocorticoids (GCs) are frequently used in combination with docetaxel, it is unclear to what extent GCs and their receptor, the glucocorticoid receptor (GR), contribute to the chemotherapy resistance. I...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Endocr Relat Cancer
Päätekijät: Kroon, Jan, Puhr, Martin, Buijs, Jeroen T, van der Horst, Geertje, Hemmer, Daniëlle M, Marijt, Koen A, Hwang, Ming S, Masood, Motasim, Grimm, Stefan, Storm, Gert, Metselaar, Josbert M, Meijer, Onno C, Culig, Zoran, van der Pluijm, Gabri
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Bioscientifica Ltd 2016
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4657186/
https://ncbi.nlm.nih.gov/pubmed/26483423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-15-0343
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia